CJC-1295 / Ipamorelin Blend

The CJC-1295 / Ipamorelin blend combines two synthetic research peptides that are marketed together for growth-hormone support. Neither component is approved by the FDA for any use, human data are limited, and both are banned in sport by the World Anti-Doping Agency. This page is educational information, not medical advice. It does not endorse using these materials, and any decision about your health should be made with a licensed clinician.

What is CJC-1295 / Ipamorelin Blend?#

This is not a single drug but a mixture of two separate peptides that vendors sell pre-combined:

• CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It is designed to stimulate the pituitary gland to release growth hormone. It comes in two forms: a long-acting version "with DAC" (a Drug Affinity Complex that binds albumin and extends its reported half-life to days), and a short-acting version "without DAC," often called Modified GRF 1-29.
• Ipamorelin is a synthetic pentapeptide (five amino acids) classified as a selective ghrelin/growth-hormone-secretagogue-receptor (GHS-R) agonist. In early studies it stimulated growth hormone release with comparatively little effect on cortisol or prolactin, which is why it is described as relatively "selective."

The two are blended because they act on the growth-hormone axis through different but complementary pathways — a GHRH analog plus a ghrelin-receptor agonist — and sellers suggest the pairing might produce a larger or more sustained GH response. It is important to understand that the blend as a product has not itself been the subject of published human studies; the rationale for combining them is largely a marketing convention rather than an established, evidence-based protocol.

How does CJC-1295 / Ipamorelin Blend work?#

The proposed mechanisms come from the known pharmacology of each peptide individually:

• CJC-1295 mimics GHRH and binds the GHRH receptor on the pituitary, promoting the release of growth hormone (and, downstream, IGF-1). In an early single-dose human pharmacology study, the DAC form raised GH and IGF-1 levels for an extended period (Teichman et al., 2006).
• Ipamorelin acts on a different receptor — the growth-hormone-secretagogue (ghrelin) receptor — to trigger a pulse of growth-hormone release. In its original characterization it was notable for releasing GH with relatively little increase in cortisol and prolactin compared with some other secretagogues (Raun et al., 1998).

These are proposed mechanisms based largely on early pharmacology and animal models. They have not been confirmed to produce safe or meaningful long-term effects in humans, and laboratory mechanisms frequently fail to translate into real-world clinical benefit. The combination specifically has no published human trials.

What is CJC-1295 / Ipamorelin Blend studied for?#

Most claims trace back to early pharmacology research on the two peptides separately. The table below summarizes common research themes and how strong the human evidence is.

A notable limitation: the strongest human data point is a single early single-dose study of CJC-1295 with DAC, and ipamorelin's clinical development was discontinued — neither supports the marketed blend as a proven product.

Is CJC-1295 / Ipamorelin Blend legal and FDA-approved?#

Neither component is FDA-approved.

• FDA status: Neither CJC-1295 nor ipamorelin is an FDA-approved drug, and neither is a lawful dietary supplement ingredient. The FDA has reviewed peptide growth hormone secretagogues as part of its bulk drug substances evaluation for compounding under section 503A and flagged this class as raising safety concerns and unsuitable for compounding. They remain unapproved drugs and are frequently sold labeled "research use only" or "not for human consumption."
• Sport status: Both CJC-1295 and ipamorelin fall under the WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — growth-hormone-releasing peptides and secretagogues are banned at all times, in and out of competition. Athletes have been sanctioned for their use, and military service members are warned against products containing these peptides.

Selling, marketing, or buying these as human-use products is legally fraught, and the "research chemical" labeling does not make human use safe or lawful.

How is CJC-1295 / Ipamorelin Blend dosed in research?#

There is no validated human dose for CJC-1295, ipamorelin, or the blend. The one human study of CJC-1295 with DAC (Teichman et al., 2006) used single subcutaneous research doses on a per-kilogram basis to characterize pharmacokinetics — not a regimen for the marketed no-DAC blend. Because adequate efficacy and safety trials have not been conducted, no one has established a dose that is known to be safe or effective, and no governing health authority has issued dosing guidance.

WikiPeps does not publish dosing protocols or amounts for these peptides. Any question about whether a peptide could be appropriate, and in what form or amount, should be directed to a licensed clinician who can weigh your individual medical history and the substantial unknowns involved.

How is CJC-1295 / Ipamorelin Blend reconstituted?#

These peptides are typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic or sterile water before any handling. The frontmatter on this page includes a generic, education-only overview of the reconstitution steps, with no volumes or concentrations. For a fuller walkthrough of sterile technique, supplies, and storage, see our general guide at /learn/guides/how-to-reconstitute-a-peptide.

Reconstitution instructions describe laboratory handling only. They are not an endorsement of use and do not substitute for guidance from a licensed clinician.

What are the safety considerations?#

• Unknown human safety. With no adequate human trials of the combination, the long-term risks, drug interactions, and safe dose (if any) are unknown for both peptides and especially for the combination.
• Growth-axis effects. Because these peptides are designed to raise growth hormone and IGF-1, there are theoretical concerns about effects on blood sugar (insulin resistance), fluid retention, joint discomfort, and the possibility of supporting the growth of an existing, undetected tumor. These have not been resolved in humans.
• Product quality risk. Material sold as a research chemical is not manufactured to pharmaceutical standards. Purity, sterility, correct identity, and accurate labeling are not guaranteed, and contamination or mislabeling is a real possibility.
• Injection risks. These products are typically injected after reconstitution, which carries risks of infection, injection-site reactions, and harm from non-sterile technique.
• Regulatory and sport consequences. Use can result in anti-doping sanctions for athletes and is incompatible with rules for military service members and many employers.
• Not a substitute for care. Self-treating a perceived deficiency with an unapproved peptide may delay appropriate, evidence-based medical care.

If you are considering anything in this category, talk with a licensed clinician first. If you experience a reaction or adverse event, seek medical attention.

The bottom line#

The CJC-1295 / Ipamorelin blend pairs two synthetic peptides that are both unapproved research chemicals, not medicines. The human evidence is limited to early pharmacology of the individual components, the combination has no published human studies, and both are banned in sport by WADA. Human safety, effectiveness, and dosing are not established. This page is educational only and is not medical advice; decisions about your health should be made with a qualified, licensed clinician.